Dr. Benjamin Joshua Zigun, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 248 Seymour Ave, Griffin Hospital, Derby, CT 06418 Phone: 203-732-7550 Fax: 203-732-1550 |
Dr. Raina Sotsky, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 30 Elizabeth St, Derby, CT 06418 Phone: 203-954-0543 |
Dr. Joseph Blaise Guarnaccia, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 350 Seymour Ave # 1c, Derby, CT 06418 Phone: 203-732-1290 Fax: 203-732-1299 |
Dr. Edward Halstead, M.D. Psychiatry & Neurology - Addiction Medicine Medicare: Medicare Enrolled Practice Location: 130 Division St, Derby, CT 06418 Phone: 203-732-7403 Fax: 203-732-7177 |
Dr. Gordon Kuster, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 130 Division St, Derby, CT 06418 Phone: 203-732-7403 Fax: 203-732-7177 |
Mihaela Boran, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 130 Division St, Derby, CT 06418 Phone: 203-735-7421 |
Dr. Michael Jay Lustick, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 30 Elizabeth St, Derby, CT 06418 Phone: 203-954-0543 |
Michael Kligfeld, MD Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 300 Seymour Ave, Derby, CT 06418 Phone: 203-735-9009 |
News Archive
The patented 96-well Multi-Tier Microplate System from Porvair Sciences and sister company - JG Finneran is a unique device providing analysts with the convenience of an ANSI/SLAS microplate footprint but loaded with inert glass vials.
Microchip Technology Inc., a leading provider of microcontroller and analog semiconductors, today announced a new Medical Design Partner Specialist. TechEn, Inc. joins Microchip's program of more than 14 Design Partner Specialists in areas such as medical electronics, Radio-Frequency (RF) design and touch sensing.
TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.
Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of TafinlarĀ® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.
› Verified 3 days ago